Funding for this research was provided by:
National Institutes of Health (P30 CA008748)
Article History
Accepted: 3 July 2023
First Online: 10 July 2023
Declarations
:
: Andrew L. Lin reports that he has received funding from Bristol-Myers Squibb. Robert J. Young reports that he has consulted for Olea Sphere and ICON plc, unrelated to this work. The remaining authors have nothing to disclose.
: This patient provided written informed consent to a protocol, which was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB) and was conducted in accordance with International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws (NCT01775072). This protocol permits sequencing of tumoral cell free DNA in plasma and collection and reporting of clinical data.